VOLUME 10 (2019)
View Archive »
About The Cover
The cover for issue 20 of Oncotarget features Figure 5, "Combination treatment of GNF5 and docetaxel induces cytoplasmic localization of Yap1 and decreases expression of downstream transcription targets of Yap1 compared to vehicle control treated lung adenocarcinomas," by Khatri, et al.
|
|
Table of Contents
News
|
| Harnessing the synergistic potential of biologically targeted therapies in cutaneous Tcell lymphoma |
|
https://doi.org/10.18632/oncotarget.26751
|
| 1860-1861 |
Editorial
|
| Neglected players: Tumor associated neutrophils involvement in chronic lymphocytic leukemia progression |
|
https://doi.org/10.18632/oncotarget.26716
|
| 1862-1863 |
|
| Place of residence and childhood cancer survival |
|
https://doi.org/10.18632/oncotarget.26717
|
| 1864-1865 |
|
| Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy |
|
https://doi.org/10.18632/oncotarget.26749
|
| 1866-1867 |
|
| Risk stratification for melanoma |
|
https://doi.org/10.18632/oncotarget.26755
|
| 1868-1869 |
|
| Veryhighrisk VHR localized prostate cancer: an indication for multimodal therapy |
|
https://doi.org/10.18632/oncotarget.26757
|
| 1870-1871 |
|
| Antitumor activity of stem cellderived extracellular vesicles |
|
https://doi.org/10.18632/oncotarget.26759
|
| 1872-1873 |
Priority Research Papers
|
| ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation |
|
https://doi.org/10.18632/oncotarget.26740
|
| 1874-1886 |
Research Papers
|
| Estrogen stimulates female cancer progression by inducing myeloidderived suppressive cells: investigations on pregnant and nonpregnant experimental models |
|
https://doi.org/10.18632/oncotarget.26711
|
| 1887-1902 |
|
| PDL1 upregulation in myeloma cells by panobinostat in combination with interferonγ |
|
https://doi.org/10.18632/oncotarget.26726
|
| 1903-1917 |
|
| Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome |
|
https://doi.org/10.18632/oncotarget.26727
|
| 1918-1931 |
|
| Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia |
|
https://doi.org/10.18632/oncotarget.26735
|
| 1932-1942 |
|
| Monocytetomacrophage switch reversibly impaired by Ibrutinib |
|
https://doi.org/10.18632/oncotarget.26744
|
| 1943-1956 |
|
| An oncolytic adenovirus 11p vector expressing adenovirus death protein in the E1 region showed significant apoptosis and tumourkilling ability in metastatic prostate cells |
|
https://doi.org/10.18632/oncotarget.26754
|
| 1957-1974 |
|
| Specific allelic variants of SNPs in the <i>MDM2</i> and <i>MDMX</i> genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients |
|
https://doi.org/10.18632/oncotarget.26768
|
| 1975-1992 |
|
| A global immune gene expression signature for human cancers |
|
https://doi.org/10.18632/oncotarget.26773
|
| 1993-2005 |
Corrections
|
| Correction: The role of indoxyl sulfate in renal anemia in patients with chronic kidney disease |
|
https://doi.org/10.18632/oncotarget.26782
|
| 2006-2006 |
|
| Correction: Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts |
|
https://doi.org/10.18632/oncotarget.26783
|
| 2007-2007 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
